))
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest ...
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Justin Arnall, PharmD, BCOP, CPP Guest: Jerry L. Spivak MD, MACP While managing patients with myelofibrosis, there are certain indications that it may be time to switch therapies. And working with your patient will help with a timely and seamless transition. To learn more about these best practices, j…
…
continue reading
Guest: Justin Arnall, PharmD, BCOP, CPP Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerry L. Spivak MD, MACP After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the ove…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, div…
…
continue reading
Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremb…
…
continue reading
Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this di…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized care becoming increasingly important in the second-line setting. Joining Dr. Charles Turck to discuss how CAR T-cell therapy a…
…
continue reading
Guest: Matthew Lunning, DO, FACP It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as th…
…
continue reading
Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell th…
…
continue reading
Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a …
…
continue reading
Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in…
…
continue reading
Host: Jacob Sands, MD Guest: Aakesh Desai, MD, MPH According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr…
…
continue reading
Host: Zachery Reichert MD, PhD If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with D…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tomasz Beer, MD, FACP Guest: Betsy O'Donnell, MD Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to pot…
…
continue reading
Guest: Jessica E. Hawley M.D. M.S. For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each …
…
continue reading
Host: Daniel Kwon, MD Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for V…
…
continue reading
Host: Neal Shore, MD Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalut…
…
continue reading
Guest: Jessica E. Hawley M.D. M.S. The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the Univ…
…
continue reading
